Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.

ABSTRACT: Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially

SUBMITTER: Frustaci AM 

PROVIDER: S-EPMC10000925 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature